Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02741596 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 212
- Enrollment target
NCT02741596 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 212 participants.
The verdict
NCT02741596, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 212 participants
- Enrollment target
Study Summary
This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.
Interventions
- DRUG DX-2930
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2016-05-26 |
| Est. Completion | 2019-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02741596
The ClinicalTrials.gov registry entry for NCT02741596 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DX-2930 is the first listed.
NCT02741596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02741596 about?
NCT02741596 is a clinical study titled "Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE". This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.
What is the current status of trial NCT02741596?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 212 participants. The study started on 2016-05-26. Estimated completion is 2019-10-31.
What interventions are being tested in trial NCT02741596?
The interventions under investigation include: DX-2930 (DRUG).
Who is sponsoring clinical trial NCT02741596?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.